Skip to main content
Equibles
VKTX logo

VKTX · Viking Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track VKTX — free

Use VKTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VKTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$32.26 -0.44 (-1.35%)
Russell 1000 member Rebalance outlook locked
Market Cap
$3.81B
Shares
116.65M

Viking Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Viking Therapeutics, Inc. (VKTX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$15.77M '22 Q3 22-10-26 · $ −$19.56M '22 Q4 23-02-08 · $ −$19.53M '23 Q1 23-04-26 · $ −$19.23M '23 Q2 23-07-26 · $ −$22.53M '23 Q3 23-10-25 · $ −$24.61M '23 Q4 24-02-07 · $ −$27.36M '24 Q1 24-04-24 · $ −$22.25M '24 Q2 24-07-24 · $ −$24.94M '24 Q3 24-10-23 · $ −$35.42M '24 Q4 25-02-05 · $ −$45.63M '25 Q1 25-04-23 · $ −$65.56M '25 Q2 25-07-23 · $ −$90.79M '25 Q3 25-10-22 · $ −$157.66M '25 Q4 26-02-11 · $ −$158.32M '26 Q1 26-04-29 LATEST · $ −$128.02M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Confident tone VK2735 subcutaneous Phase III Vanquish program VK2735 oral tablet Phase 3 program Financial position and burn
Revenue
$
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
Confident tone VK2735 subcutaneous Phase III Vanquish program Maintenance dosing study Oral VK2735 Phase III development
Revenue
$
Diluted EPS
$-1.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Confident tone Subcutaneous VK2735 Phase III VANQUISH program Manufacturing and supply chain (CordenPharma, auto-injector) Amylin agonist pipeline expansion
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-22
Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript
Confident tone VK2735 subcutaneous Phase III VANQUISH program Oral VK2735 VENTURE-Oral Dosing Trial Maintenance dosing study
Revenue
$
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-23
Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript
Confident tone VK2735 subcutaneous VANQUISH Phase III program VK2735 oral formulation and Phase II results Amylin receptor agonist program and IND filing
Revenue
$
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call
Revenue
$
Diluted EPS
$-0.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-05
Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Call Transcript
Confident tone VK2735 subcutaneous obesity program (VENTURE) VK2735 oral tablet for obesity Phase 3 planning for VK2735
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-23
Viking Therapeutics, Inc. (VKTX) Q3 2024 Earnings Call Transcript
Confident tone VK2735 subcutaneous obesity program (VENTURE Phase 2) VK2735 oral formulation VK2809 NASH/fibrosis program (VOYAGE)
Revenue
$
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Viking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call Transcript
Confident tone VK2735 subcutaneous Phase 2 VENTURE trial VK2809 NASH VOYAGE trial Oral VK2735 formulation
Revenue
$
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcript
Confident tone Subcutaneous VK2735 Phase II VENTURE results in obesity VK2809 Phase IIb VOYAGE study in NASH Oral VK2735 tablet formulation development
Revenue
$
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-07
Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript
Confident tone VK2735 obesity program (VENTURE Phase II) VK2809 NASH program (VOYAGE) VK2735 oral formulation Phase I
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Viking Therapeutics, Inc. (VKTX) Q3 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-26
Viking Therapeutics, Inc. (VKTX) Q2 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Viking Therapeutics, Inc. (VKTX) Q1 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Viking Therapeutics, Inc. (VKTX) Q4 2022 Earnings Call Transcript
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Viking Therapeutics, Inc. (VKTX) Q3 2022 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Viking Therapeutics, Inc. (VKTX) Q2 2022 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Viking Therapeutics, Inc. (VKTX) Q1 2022 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-09
Viking Therapeutics, Inc. (VKTX) Q4 2021 Earnings Call Transcript
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Viking Therapeutics, Inc. (VKTX) Q3 2021 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Viking Therapeutics, Inc. (VKTX) Q2 2021 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Viking Therapeutics, Inc. (VKTX) Q1 2021 Earnings Call Transcript
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Viking Therapeutics, Inc. (VKTX) Q4 2020 Earnings Call Transcript
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Viking Therapeutics, Inc. (VKTX) Q3 2020 Earnings Call Transcript
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
Viking Therapeutics, Inc. (VKTX) Q2 2020 Earnings Call Transcript
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Viking Therapeutics, Inc. (VKTX) Q1 2020 Earnings Call Transcript
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 1607678 CUSIP 92686J106 13F (30d) 235 filings 234 filers Visit website Investor relations